semaglutide patent novo nordisk Ozempic's problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Patent expires next year: Novo

The most commonly reported adverse reactions in clinical trials include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and constipation, which occur in a substantial proportion of patients

This review summarizes our current knowledge concerning the role of taurine, TauCl and TauBr in the pathogenesis of inflammatory diseases initiated or propagated by MPO-derived oxidants

Age-related decreases in amino acids compromise cognitive function

In Michigan, the statute of limitations for product liability is three years

Effects of once-weekly semaglutide on appetite, energy intake, control of eating and food preference in subjects with obesity: The STEP Appetite randomized clinical trial

Evidence: A crossover study in healthy Italian volunteers compared a single high oral dose of SAG (3.5 g as powder dissolved in water) with the same dose of regular L-glutathione (3.5 g as capsules)